### ü´† Heart Failure: Cardiogenic Shock Management

#### ‚úÖ True Statements
1. **Cardiogenic shock** is characterized by signs and symptoms of **low cardiac output with hypotension** (systolic blood pressure <90 mm Hg or mean arterial blood pressure <60 mm Hg) and **evidence of end-organ hypoperfusion**, including **decreased mentation**, **cool extremities**, **low urine output**, or **lactate levels above 2.0 mEq/L (2.0 mmol/L)**.
2. Treatment of **cardiogenic shock** focuses on **remedying reversible causes** (especially **myocardial ischemia** with **revascularization**) and **supporting blood pressure and cardiac output** with **inotropic and vasopressor agents**.
3. **Percutaneous mechanical support** is an option in **severe cardiogenic shock** unresponsive to **vasopressor and inotropic therapy**.
4. Options for **percutaneous mechanical support** include **intra-aortic balloon pumps**, **percutaneous ventricular assist devices**, and **extracorporeal membrane oxygenators**.
5. **Intra-aortic balloon pump placement** is a reasonable next step in **severe cardiogenic shock with ongoing hypoperfusion** despite inotropic therapy.
6. **Biventricular pacemakers** are not indicated for patients in **cardiogenic shock** due to a lack of supporting evidence.
7. **Coronary angiography** is not indicated when **prior angiography within 1 year shows normal coronary arteries** and **no new ischemic symptoms** are present.
8. **Pulmonary artery pressure sensors** have **no known role** in the **acute management** of cardiogenic shock.

#### üí¨ Extra
1. End-organ hypoperfusion signs reflect inadequate systemic perfusion and guide the diagnosis of shock severity.
2. Revascularization is a key intervention if cardiogenic shock is due to acute coronary syndrome.
3. These devices provide hemodynamic support and are increasingly used in critical care.
4. Device choice depends on institutional resources and the patient‚Äôs clinical trajectory.
5. The case describes a patient with persistent hypoperfusion on dobutamine therapy, indicating need for mechanical support.
6. Biventricular pacing may reduce mortality in chronic heart failure but is not supported in acute shock scenarios.
7. The decision against repeat coronary angiography is based on recent normal findings and low pretest probability.
8. These sensors are used in chronic outpatient heart failure management, not in urgent inpatient shock care.

#### üìá Tags
#CardiogenicShock #HeartFailure #MechanicalCirculatorySupport #IntraAorticBalloonPump #Vasopressors #Dobutamine #CriticalCare

#### üìö Reference
Kapur NK, Kanwar M, Sinha SS, et al. Criteria for defining stages of cardiogenic shock severity. *J Am Coll Cardiol*. 2022;80:185-198. PMID: 35835491 doi:10.1016/j.jacc.2022.04.049

#### üÜî Question ID
CVMCQ24086

#### üïí Last Updated
January 2025

---

#### üìñ Related Text
MKSAP 19: Cardiovascular Medicine ‚Äî Heart Failure, Management of Heart Failure, Acute Decompensated Heart Failure

---

### üìò Related Text Derivations

#### ‚úÖ True Statements
1. **Cardiogenic shock** is characterized by **low cardiac output**, **hypotension**, and **end-organ hypoperfusion**, including **decreased mentation**, **cool extremities**, **low urine output**, or **lactate levels >2.0 mEq/L (2.0 mmol/L)**.
2. Initial treatment of **cardiogenic shock** includes **reversing the cause**, such as **reperfusion** in **acute coronary syndrome**, and **supporting blood pressure and cardiac output** with **inotropes and vasopressors**.
3. **Early recognition of cardiogenic shock** and **aggressive support** with **pressors** and **percutaneous assist devices** or **transfer to a shock center** are important to improve survival.
4. **Percutaneous mechanical support devices** can be placed rapidly to stabilize **critically ill patients**, including **intra-aortic balloon pumps**, **ventricular assist devices**, and **extracorporeal membrane oxygenators**.
5. A **shock team** consisting of a **heart failure physician**, **critical care physician**, and **cardiac surgeon** is recommended to rapidly deploy therapy and coordinate **postprocedure care**.
6. For patients who **do not improve clinically**, daily discussions should address **treatment goals**, including **transplantation**, **permanent left ventricular assist device (LVAD)** placement, or **palliative care**.

#### üí¨ Extra
1. Lactate is a biochemical marker of impaired perfusion.
2. Acute coronary syndrome is the most common reversible cause of cardiogenic shock.
3. Specialized centers may offer advanced therapies and better outcomes.
4. Mechanical circulatory support helps bridge to recovery or decision.
5. Multidisciplinary teams improve speed and coordination of critical interventions.
6. Decision-making includes ongoing assessment for candidacy for advanced therapies or comfort-focused care.

#### üè∑Ô∏è Tags
#CardiogenicShock #CriticalCare #MechanicalSupport #HeartFailure #LVAD #ShockTeam #PalliativeCare #PerfusionMarkers

---

#### üñºÔ∏è Supplemental Tables

<table>
  <caption><strong>Mechanical Circulatory Support Options in Cardiogenic Shock</strong></caption>
  <thead>
    <tr>
      <th>Device</th>
      <th>Mechanism</th>
      <th>Indications</th>
      <th>Considerations</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Intra-aortic balloon pump (IABP)</td>
      <td>Reduces afterload and augments coronary perfusion</td>
      <td>Severe cardiogenic shock unresponsive to inotropes</td>
      <td>Widely available; contraindicated in aortic regurgitation</td>
    </tr>
    <tr>
      <td>Percutaneous ventricular assist device (e.g., Impella)</td>
      <td>Provides forward flow from left ventricle to aorta</td>
      <td>Refractory cardiogenic shock or bridge to recovery</td>
      <td>Risk of vascular injury; requires anticoagulation</td>
    </tr>
    <tr>
      <td>Extracorporeal membrane oxygenation (ECMO)</td>
      <td>Bypasses heart and lungs; full hemodynamic and gas exchange support</td>
      <td>Profound cardiopulmonary failure</td>
      <td>Requires specialized team; high bleeding risk</td>
    </tr>
  </tbody>
</table>